A Study to Evaluate Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes


About this study

The primary research hypothesis is that in the modern cardiac catheterization laboratory, where PCI procedural duration is relatively short and rates of intracoronary stenting and dual antiplatelet therapy use is high, lower ACT targets, as compared with higher ACT targets, will be associated with lower rates of bleeding while having similar rates of ischemic events.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria: 

  • Adults, age >18 years old.
  • Adult patients referred for coronary angiography with possible coronary revascularization or adjunctive invasive diagnostic testing (IVUS/OCT, FFR, or iFR).

Exclusion Criteria: 

  • Receipt of LMWH at treatment dose (not DVT prophylaxis dose) within 6 hours of coronary angiography.
  • Prior GP IIb/IIIa use within the previous 72 hours.
  • Use of warfarin (vitamin K antagonist) or direct oral anticoagulant.
  • Patients on LMWH bridging strategy.
  • PCI within prior 30 days. 
  • Planned use of bivalirudin as the procedural anticoagulant.
  • Rotational atherectomy. 
  • Excimer laser coronary angioplasty.
  • Chronic total occlusions. 
  • Patients with active bleeding disorders or bleeding diathesis.
  • Patients with ST-segment elevation myocardial infarction.
  • Patient with clinical evidence of cardiogenic shock (defined as SBP<90 mmHg for ≥30 min OR support to maintain SBP ≥90 mmHg AND evidence of end-organ hypoperfusion (urine output <30 mL/h or cool extremities).
  • Chronic kidney disease stage 4/5 (GFR 30 mL/min).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Shahyar Gharacholou, M.D., M.S.

Open for enrollment

Contact information:

Inna Abrea B.S.



Rochester, Minn.

Mayo Clinic principal investigator

Shahyar Gharacholou, M.D.

Contact us for the latest status

Contact information:

Shahyar Gharacholou M.D.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer